Home » Topics » Gastrointestinal, BioWorld Science

Gastrointestinal, BioWorld Science
RSS

XTL reports on phase I testing of XTL-001 at investor conference

Feb. 17, 2000

Novartis files for U.S., European approval of new IBS treatment

Feb. 17, 2000

Patient dosing begins in phase I study of first anti-HCV ribozyme therapy

Feb. 17, 2000

Vion licenses potential HBV/HIV therapy to Achillion

Feb. 14, 2000

FDA to review Schering-Plough's BLA for PEG-Intron

Feb. 11, 2000

FDA approves Lotronex for IBS in women

Feb. 10, 2000

AxyS enters drug design agreement with Bristol-Myers Squibb

Feb. 9, 2000

Gastric antisecretory agents from KRICT superior to omeprazole in vitro and in vivo

Feb. 8, 2000

FDA approves tablet formulation of Protonix for erosive esophagitis

Feb. 7, 2000

New oral IBD treatment targets macrophages and microfold cells

Feb. 1, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 8, 2026.
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.